Open Access | Editorial
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Stricter definitions of myeloid senescence are needed
* Corresponding author: Brandt Pence
Mailing address: 495 Zach H Curlin St., Memphis, TN 38152,
USA.
Email: bdpence@memphis.edu
Received: 13 June 2024 / Accepted: 14 June 2024 / Published: 27 June 2024
DOI: 10.31491/APT.2024.06.139
Abstract
Cellular senescence is a state of irreversible cell cycle arrest that is associated with age-related diseases. There is considerable interest in studying senescence in immune cells such as macrophages. However, current popular markers of cellular senescence overlap substantially with cellular programs induced in macrophages and related cells during acute inflammation responses, raising questions about the degree to which the current literature truly reflects senescence in the innate immune system.
Keywords
Senescence, macrophage, monocyte, dendritic cell, immune aging
Cellular senescence is classically defined as an irreversible state of cell cycle arrest [1]. Senescence is a hallmark
of aging, with increased senescent cell burden in a variety
of tissues with advancing age. Senescent cells are thought
to contribute to pathology of a variety of age-related diseases including cardiovascular and renal disease, diabetes,
and Alzheimer’s disease, with the strongest evidence being amelioration or reduction of disease through selective
senescent cell removal with various senolytic drugs [1].
Senescent cells mediate disease and propagate senescence
to other cells through secretion of a suite of proteins
known as the senescence-associated secretory phenotype
(SASP) [2], which includes a variety of pro-inflammatory
cytokines, growth factors, and chemokines.
Although most work in cellular senescence has examined fibroblasts, endothelial cells, and other major tissue
resident cell types, there has been some interest in studying cellular senescence in the immune system. A seminal
paper in Science in 2016 purported to link cellular senescence to disease mediated by macrophages, showing
that foam cells in atherosclerotic plaques have increased
senescence-associated markers and SASP constituents
[3]. Senescence in macrophages has been of tremendous
interest in recent years, with more than 600 papers per
year matching the search term “senescence AND macrophages” since 2020.
The topic of macrophage senescence has been comprehensively reviewed very recently [4], and interested readers
can find significantly more information about this topic in
that paper than is possible to include in this format. My
purpose here is to point out several concerns with the current literature on senescence in macrophages (and similar
cell types such as monocytes and dendritic cells). While it
is by no means conclusive that the cells described in many
of these papers are not senescent, the available evidence is
also not sufficient to conclusively state that they are true
senescent cells.
The majority of the senescence literature, including that
pertaining to immune cells, defines senescent cells on the
basis of some combination of (a) increased expression
of the enzyme β-galactosidase (β-gal), (b) upregulation
of the cell cycle protein p16INK4A or its encoding gene
CDKN2A, and/or (c) expression of some interrogated
subset of known SASP proteins. This is problematic in innate immune cells for a variety of reasons. In the last case,
defined SASP proteins (many being pro-inflammatory cytokines) have substantial overlap with proteins produced
by macrophages and other immune cells during acute
inflammatory activation. This makes distinguishing acute
inflammation responses from cellular senescence difficult,
especially in shorter-term in vitro experiments.
With respect to other routine senescence markers, a notable paper by Hall et al. [5] demonstrated that both β-gal
expression and p16 activation are upregulated in a reversible manner in macrophages during acute polarization
responses. This conflicts with the definition of senescence
in most cell types, where a key facet is its irreversible
nature. Many other papers have shown these markers to
be activated in immune cells during biological responses
which are decidedly not senescence. For example, we
have previously shown acute increases in CDKN2A expression in monocytes within hours after activation by the
spike protein from SARS-CoV-2 [6]. Relatedly, the overlap between senescence and immune activation makers
raises the question of whether some effects attributed to
senolytic drugs may be due to the nonselective removal or
suppression of innate immune responses as well.
As such, traditional markers of senescence are not likely
to be sufficient (by themselves) to define innate immune
cells as senescent. There are other established markers
of senescence including those that reflect DNA damage
which might be useful [7], but this will require extensive
study. Some effort has been made with single cell sequencing to define unique markers of macrophage senescence (reviewed in [4]), but this area is in its infancy and
suffers from the same uncertainty in defining innate immune cells as senescent as in the other literature described
above. Irradiation-induced macrophage senescence in in
vitro studies seems a promising place to start when developing macrophages which are probably senescent rather
than acutely activated, and some progress has been made
in this area [4].
Finally, from a philosophical (or perhaps teleological)
perspective, the purpose of replicative senescence in innate immune cells such as macrophages is rather unclear.
Macrophages and other myeloid cells are primarily postmitotic and do not replicate to any great degree (beyond
perhaps to permit self-renewal in resident tissue macrophages [8]), so the biological purpose of a senescence program in these cell types is murky. Given all of the above,
some care should be taken when defining macrophages
and similar cell types as senescent.
Declarations
Financial support and sponsorship
None.
Conflict of interest statement
Brandt Pence is an Associate Editor of Aging Pathobiology and Therapeutics. He declares no conflict of interest and was not involved in the journal’s review or decisions related to this manuscript.
Ethics approval and consent to participate
Not applicable.
References
1. Zhang L, Pitcher LE, Yousefzadeh MJ, Niedernhofer LJ, Robbins PD, & Zhu Y. Cellular senescence: a key therapeutic target in aging and diseases. J Clin Invest, 2022, 132(15): 158450. [Crossref]
2. Wang B, Han J, Elisseeff JH, & Demaria M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat Rev Mol Cell Biol, 2024. [Crossref]
3. Childs BG, Baker DJ, Wijshake T, Conover CA, Campisi J, & van Deursen JM. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science, 2016, 354(6311): 472-477. [Crossref]
4. Wang L, Hong W, Zhu H, He Q, Yang B, Wang J, et al. Macrophage senescence in health and diseases. Acta Pharm Sin B, 2024, 14(4): 1508-1524. [Crossref]
5. Hall BM, Balan V, Gleiberman AS, Strom E, Krasnov P, Virtuoso LP, et al. p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Aging (Albany NY), 2017, 9(8): 1867-1884. [Crossref]
6. Cory TJ, Emmons RS, Yarbro JR, Davis KL, & Pence BD. Metformin suppresses monocyte immunometabolic activation by SARS-CoV-2 spike protein subunit 1. Front Immunol, 2021, 12: 733921. [Crossref]
7. González-Gualda E, Baker AG, Fruk L, & Muñoz-Espín D. A guide to assessing cellular senescence in vitro and in vivo. Febs j, 2021, 288(1): 56-80. [Crossref]
8. Mass E, Nimmerjahn F, Kierdorf K, & Schlitzer A. Tissuespecific macrophages: how they develop and choreograph tissue biology. Nat Rev Immunol, 2023, 23(9): 563- 579. [Crossref]